Cannara Hits Bay Street: A New Era for the Cannabis Producer on the TSX

MONTREAL, QC – February 26, 2026 – Cannara Biotech Inc. is set to make its debut on Canada's senior stock exchange, a move that solidifies its position as a major player in the nation's evolving cannabis industry. The Québec-based producer announced it has received final approval to graduate from the TSX Venture Exchange (TSXV) to the Toronto Stock Exchange (TSX), with trading slated to begin on March 2, 2026.

The company will trade under its familiar ticker symbol, 'LOVE', a symbol that now represents a company entering a new phase of corporate maturity and investor appeal. The uplisting is more than a symbolic gesture; it is a strategic milestone expected to unlock greater access to capital and enhance the company's profile among a broader class of institutional and retail investors. This development, coupled with fresh analyst coverage from a major bank, signals a significant validation of Cannara's strategy and financial performance in a market still navigating its path to stability.

A Bay Street Milestone and Market Validation

The transition to the TSX marks the culmination of a period of significant growth for Cannara. As its shares commence trading on the main board on March 2, they will be concurrently delisted from the TSXV. To commemorate the achievement, Cannara executives will have the honour of opening the market at the TSX on March 17, 2026.

"Graduating to the TSX represents a significant milestone in Cannara's evolution as a public company," said Zohar Krivorot, Founder and CEO of Cannara, in the official announcement. "This achievement enhances our market visibility and liquidity while broadening our accessibility to institutional investors. It reflects the progress we have made as an organization and our commitment to building long-term shareholder value as we continue executing on our growth strategy."

Adding to the momentum, financial services firm TD Cowen initiated coverage on Cannara on February 24, issuing a "Buy" rating and a C$3.25 price target. For a company preparing to step onto a larger stage, such an endorsement from a reputable institution is a powerful signal to the market. It suggests a growing confidence in Cannara's business model and its potential for future growth, providing a data point for investors who may have previously overlooked the company on the venture exchange. This dual development—uplisting and positive analyst coverage—serves as a powerful one-two punch, validating the company's operational and financial discipline.

The Financial Engine Driving Growth

Cannara's ascent to the TSX is not built on speculation but on a foundation of robust and improving financial results. The company has distinguished itself in the often-turbulent cannabis sector by achieving consistent profitability and positive cash flow, metrics that have eluded many of its competitors.

For its fiscal year ending August 31, 2025, Cannara reported record-breaking figures, including net revenues of $107.3 million and an adjusted EBITDA of $28.1 million. Perhaps most notably, the company posted a net income of $13.1 million and, for the first time, achieved positive retained earnings—a critical indicator of sustainable profitability. This performance generated an impressive $20 million in operating cash flow and $13.7 million in free cash flow, underscoring the efficiency of its operations.

This strong performance has continued into the new fiscal year. For the first quarter of 2026, which ended November 30, 2025, Cannara reported a 7% quarter-over-quarter increase in gross cannabis revenues to $41.8 million. Net revenues after Canada's substantial excise taxes climbed to $30.1 million. Adjusted EBITDA saw a significant jump of 47% compared to the same quarter in the previous year, reaching $8.8 million. This financial strength provides the company with the stability and resources needed to pursue its growth strategy without heavy reliance on dilutive capital markets, a key differentiator in the cannabis industry.

The 'Affordable Premium' Quebec Advantage

At the core of Cannara's success is a meticulously executed business model that leverages a distinct regional advantage. The company operates two massive facilities in Québec spanning a combined 1.6 million square feet, with a potential annual cultivation output of 100,000 kilograms. This scale, combined with Québec's famously low electricity costs, allows Cannara to execute its "affordable premium" strategy.

This strategy involves producing high-quality cannabis that can compete on quality with premium brands while being priced accessibly for a broader consumer base. This value proposition has resonated strongly with Canadian consumers, particularly in its home province. As of December 2025, Cannara had captured the number one market share position in Québec with 13.5% of retail sales. Its national market share has also been on a steady climb, reaching approximately 4.5%, a significant feat in a fragmented and competitive landscape.

The company's brand portfolio, which includes the popular Tribal, Nugz, and Orchid CBD lines, has become a staple in dispensaries. The recent launch of vape products in Québec in November 2025 further contributed to its strong Q1 2026 results, demonstrating an ability to adapt and capitalize on new product categories. By controlling its production from cultivation to sale (vertical integration) and optimizing its cost structure, Cannara has built a resilient and profitable operation that stands out in the Canadian market.

A Bellwether for a Maturing Cannabis Sector?

Cannara's graduation to the TSX is more than just a corporate victory; it can be viewed as a bellwether for the Canadian cannabis industry itself. After years of post-legalization volatility, market corrections, and investor skepticism, the sector is beginning to show signs of maturation. The focus is shifting away from boundless expansion promises and toward tangible metrics like profitability, market share, and operational efficiency.

Companies like Cannara, which have demonstrated a clear path to profitability and sustainable growth, are becoming increasingly attractive to a more discerning class of investors. The uplisting to a senior exchange is a critical step in attracting institutional capital, which has largely remained on the sidelines due to the risk and volatility associated with the sector. A TSX listing provides the enhanced liquidity, stricter reporting standards, and broader visibility that pension funds, mutual funds, and other large investors require.

As 2026 unfolds, analysts anticipate it will be a pivotal year for Canadian cannabis, with capital flows expected to re-accelerate toward operators with strong fundamentals. Cannara's stock performance reflects this growing optimism. Trading at C$1.83 on February 26, the stock has seen a more than 72% increase from its 52-week low. With its proven business model, strong financial footing, and now, a new home on Bay Street, Cannara Biotech is well-positioned to capitalize on the next phase of the cannabis industry's evolution. The market will be watching closely when 'LOVE' begins trading on the TSX, looking for signs of how this next chapter will unfold.